| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.036 | 0.2 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.035 | 0.2 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.18 | 0.2 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |